IngredientsValine-L-malate is a dietary supplement ingredient formed by combining two naturally occurring compounds: L-valine, an essential branched-chain amino acid (BCAA), and L-malate (the ionized form, or salt, of L-malic acid), a key organic acid and tricarboxylic acid (TCA) cycle intermediate. The product is structurally analogous to other well-known amino acid–malate conjugates in the sports nutrition market, such as citrulline malate, in which citrulline malate is an organic salt made up of an amino acid and L-malic acid, an intermediate in the citric acid cycle.
L-Valine has the molecular formula C₅H₁₁NO₂ and a molecular weight of 117.15 g/mol. Its CAS Registry Number is 72-18-4, and its IUPAC Standard InChIKey is KZSNJWFQEVHDMF-SCSAIBSYSA-N. It is also known under the synonyms L-Valine, (S)-2-amino-3-methylbutanoic acid, 2-amino-3-methylbutyric acid, and L-(+)-α-aminoisovaleric acid. Structurally, L-valine features a central carbon atom bonded to an amino group (–NH₂), a carboxyl group (–COOH), a hydrogen atom, and a distinctive isopropyl side chain (–CH(CH₃)₂). It is an aliphatic amino acid because its hydrocarbon chain is branched and without an aromatic ring structure, and it is non-polar because its functional group is uncharged at physiological pH; it does not participate in hydrogen bonding at physiological pH. It is extremely hydrophobic in nature and is generally found inside globular proteins.
L-Malic acid (the acid precursor of L-malate) is a dicarboxylic organic acid. Malic acid exists in three isomeric forms: D-, L-, and dl-malic acid; in nature, L-malic acid is the predominant form and is ubiquitously present in animal, plant, and microbial cells. L-malic acid exists in its undissociated acidic form, characterized by a molecular structure possessing two carboxylic acid (–COOH) groups. The salts and esters of malic acid are known as malate.
As a combined ingredient, valine-L-malate is most precisely described as an organic acid salt of L-valine with L-malic acid — a form in which the basic amino group of valine interacts with the acidic carboxyl groups of malic acid, analogous to the chemistry of other amino acid malate salts documented in the patent literature. This pairing is intended to deliver both the amino acid and the TCA-cycle intermediate in a single molecular complex.
Valine, like other branched-chain amino acids, is synthesized by bacteria and plants, but not by animals. It was first isolated from casein in 1901 by Hermann Emil Fischer. The name valine comes from its structural similarity to valeric acid, which in turn is named after the plant valerian due to the presence of the acid in the roots of the plant.
L-valine is primarily obtained through dietary sources such as meat, dairy, eggs, and legumes. The proteins in foods from animal and plant sources typically contain about 40–60 mg/g valine. L-malic acid gives apples and many fruits their bright tartness. Tart fruits (apples, apricots, cherries), grapes, and many fermented foods are rich in organic acids, notably malic and tartaric acids.
Dietary supplements with crystalline valine, often in combination with other amino acids, are commercially available. Valine-L-malate specifically appears in the supplement market as a powder and capsule form, positioned within pre-workout and recovery formulations. Many supplements bond an amino acid to malate to improve their bioavailability, such as citrulline malate and magnesium malate. The pharmaceutical and nutraceutical patent literature confirms that derivatives of L-valine such as esters, amides, and salts — as well as other derivatives, including derivatives that become active upon metabolism — are recognized forms of the amino acid.
In the broader family of amino acid malate salts, L-amino acid malate salts have been documented to possess activities related to ammonia detoxification and improvement of liver function, and they dissolve in water to give a neutral solution, making them suitable for oral administration.
L-Valine as an isolated compound does not have a classical traditional herbal or folk medicine history. Valine was first identified as a distinct chemical entity only at the beginning of the twentieth century. In 1901, German chemist Emil Fischer was the first person to isolate valine from casein, a protein found in dairy products as well as breast milk. As such, the ingredient predates the era of targeted amino acid supplementation by only a few decades, and there is no traditional medical system — such as Ayurveda, Traditional Chinese Medicine, or European herbalism — that specifically identified or used isolated valine.
However, the high-protein foods naturally rich in valine (meat, dairy, eggs, legumes) have been part of human diets and traditional nutritional practices across virtually all cultures throughout recorded history. The rationale behind their use for strength, endurance, and recovery is broadly attested in folk nutrition, even if the specific molecular constituent was not identified.
L-Malic acid, similarly, was not used in isolation in traditional medicine, but was consumed as a component of fruit-based preparations. Tart fruits containing malic acid have been used empirically across multiple cultures for energy, digestion, and recovery, without knowledge of their TCA cycle role.
The modern concept of amino acid–malate conjugates as targeted supplements arose in the latter decades of the twentieth century, primarily in European pharmaceutical and sports medicine contexts. Citrulline malate was initially utilized as a pharmaceutical drug (STIMOL©, BIOCODEX, Gentilly, France) for the treatment of patients suffering from asthenia, to mitigate recovery time following physical activity. The paradigm established by citrulline malate — pairing an amino acid with malate for enhanced physiological activity — subsequently informed the development of other amino acid malate conjugates, including valine-L-malate, in sports nutrition contexts.
L-valine is an essential amino acid and one of the three branched-chain amino acids (BCAAs), along with L-leucine and L-isoleucine. The essential amino acid L-valine is needed for the synthesis of proteins; it is also used as an energy fuel, and its complete oxidation requires thiamin, riboflavin, niacin, vitamin B6, vitamin B12, pantothenate, biotin, lipoate, ubiquinone, magnesium, and iron.
Protein synthesis and the mTOR pathway: BCAAs — particularly leucine — have anabolic effects on protein metabolism by increasing the rate of protein synthesis and decreasing the rate of protein degradation in resting human muscle; during recovery from endurance exercise, BCAAs were found to have anabolic effects in human muscle. These effects are likely mediated through changes in signaling pathways controlling protein synthesis, involving phosphorylation of the mammalian target of rapamycin (mTOR) and sequential activation of 70-kD S6 protein kinase (p70 S6 kinase) and the eukaryotic initiation factor 4E-binding protein 1. These effects are mediated through the phosphorylation of mTOR and sequential activation of 70-kD S6 protein kinase (p70-kD S6), and eukaryotic initiation factor 4E-binding protein 1; p70-kD S6 is known for its role in modulating cell-cycle progression, cell size, and cell survival.
Glucogenic function: Valine plays a key role in muscle metabolism, tissue repair, and the maintenance of proper nitrogen balance in the body; as one of the three BCAAs, it can be utilized as an energy source by muscle tissue; valine is a glucogenic amino acid, and therefore provides glucose.
Role of valine within the BCAA triad: Levels of isoleucine and valine decrease substantially during recovery in muscle in response to leucine ingestion alone, likely reflecting an improved net balance of muscle protein and stimulation of BCAA metabolism by leucine; the finding that muscle levels of valine and isoleucine are reduced in the leucine trial might negatively influence the rate of protein synthesis over time due to substrate depletion. Despite these observations, overall experimental support for the individual potency of isoleucine and valine in this context is limited, and it therefore seems plausible that these amino acids act synergistically with leucine.
Central fatigue hypothesis: Because BCAAs are directly metabolized in muscle tissue, they contribute to energy supply during exercise and aid in muscle recovery by participating in protein synthesis and anabolic signaling, notably through the activation of the mTOR pathway; additionally, BCAAs help reduce central fatigue by competing with tryptophan in the central nervous system, thereby influencing serotonin production.
Alanine synthesis: Valine plays a direct role in the synthesis of alanine, and therefore has a regulatory function with regards to alanine.
Blood–brain barrier transport: Leucine, isoleucine, and valine share the same large neutral amino acid transport system (LAT1) allowing entry across the blood–brain barrier, and these BCAAs are in constant competition with each other; inadequate valine and isoleucine reduces this competition, allowing a greater influx of leucine, leading to reduced brain protein synthesis and potential cerebral damage.
L-malic acid is a crucial tricarboxylic acid (TCA) cycle intermediate and gut metabolite that has transcended its traditional role as a mere metabolic substrate; it is now recognized as a multifunctional signaling molecule intricately involved in energy metabolism, redox balance, cellular signaling, and host-microbiota crosstalk.
TCA cycle participation: Malate is part of the citric acid cycle (CAC), sometimes referred to as the Krebs cycle or the tricarboxylic acid cycle (TCA); the CAC is the primary pathway that delivers energy to all areas of the body.
Malate–aspartate shuttle: L-malate, a TCA cycle intermediate, plays an important role in transporting NADH from the cytosol to mitochondria for energy production and may be involved in the beneficial effects of improving physical stamina. Under aerobic conditions, the oxidation of malate to oxaloacetate provides reducing equivalents to the mitochondria through the malate–aspartate redox shuttle.
Redox balance and anaplerosis: L-malic acid regulates redox balance, energy metabolism, and inflammation via NADPH/NADH pathways. Malate helps refill ("anaplerotic") TCA intermediates drained during intense training, fasting, or illness, supporting metabolic resilience.
Glycogen metabolism: Malate, in particular, helps regulate enzymes involved in the breakdown of glycogen (the storage form of carbohydrates) into energy.
Ammonia clearance: Malic acid supplements can promote energy substrates and regulate the level of energy metabolism, improve cardiac function, alleviate sports fatigue, and promote regeneration. Animal and human exercise studies have also suggested that malate-containing solutions may assist in reducing post-exercise blood ammonia accumulation, likely by promoting the conversion of ammonia through TCA-related pathways.
The rationale for combining L-valine with L-malate in a single salt mirrors the rationale established for citrulline malate: the malate moiety is hypothesized to potentiate the amino acid's exercise-related effects by simultaneously providing TCA cycle substrate, supporting energy production, aiding lactate and ammonia clearance, and possibly improving bioavailability or gastric tolerability of the amino acid. In the case of citrulline malate, the combination is formed through the combination of an amino acid and malate (or malic acid), a tricarboxylic acid (TCA) intermediate. Whether these same mechanistic benefits transfer to valine-L-malate as a combined salt has not been independently demonstrated in human clinical trials as of current available evidence.
Important note on evidence scope: As of the current literature, there are no published human clinical trials that have specifically tested valine-L-malate as a combined compound for any outcome. The scientific evidence base reviewed here pertains to L-valine and/or BCAAs (of which valine is a component) and to L-malate (malic acid), evaluated separately. Claims for the combined ingredient are therefore extrapolated from these two bodies of evidence and must be characterized as preliminary and indirect.
Evidence strength: Moderate for BCAAs combined; weak for valine in isolation.
The most robust evidence for valine's role in muscle physiology comes from BCAA research. A study published in Frontiers in Physiology investigated the response of myofibrillar muscle protein synthesis to ingestion of branched-chain amino acids (BCAAs) alone, without concurrent ingestion of other essential amino acids, intact protein, or other macronutrients, following resistance exercise in humans; ten young (20.1 ± 1.3 years), resistance-trained men completed two trials, ingesting either 5.6 g BCAA or a placebo drink immediately after resistance exercise. The percentage increase from baseline in plasma valine concentrations peaked 0.5 h post-drink in the BCAA group; a greater phosphorylation status of S6K1 and PRAS40 was observed in BCAA versus placebo at 1 h post-drink ingestion; myofibrillar muscle protein synthesis was 22% higher in the BCAA group (0.110 ± 0.009%/h) than placebo (0.090 ± 0.006%/h). The authors concluded that ingesting BCAAs alone increases the post-exercise stimulation of myofibrillar muscle protein synthesis and phosphorylation status of mTORC1 signaling.
A key limitation is that leucine, not valine, is the primary driver of mTORC1 activation within the BCAA triad. Overall experimental support for the individual potency of isoleucine and valine in the context of mTOR signaling is limited, and it therefore seems plausible that these amino acids act synergistically with leucine. No study has isolated valine-L-malate as a single intervention to measure muscle protein synthesis in humans.
Evidence strength: Weak to preliminary for valine specifically; moderate for L-malate-containing combinations (citrulline malate).
Branched-chain amino acids — leucine, isoleucine, and valine — play a fundamental role in muscle metabolism, acting as energy substrates and regulators of protein synthesis through mTOR pathway signaling. Because BCAAs are directly metabolized in muscle tissue, they contribute to energy supply during exercise and aid in muscle recovery.
For the malate component, animal evidence from a mouse study published in Biological & Pharmaceutical Bulletin (PubMed PMID 16555951) found that the activities of cytosolic and mitochondrial malate dehydrogenase were significantly elevated in the L-malate-treated group compared with the control group, and L-malate, a TCA cycle intermediate, plays an important role in transporting NADH from cytosol to mitochondria for energy production. In animal research, only tissue malate is depleted following exhaustive physical activity; other key metabolites from the citric acid cycle needed for energy production were found to be unchanged; because of this, a deficiency of malic acid has been hypothesized to be a major cause of physical exhaustion; administration of malic acid to rats has been shown to elevate mitochondrial malate and increase mitochondrial respiration and energy production; surprisingly, relatively small amounts of exogenous malic acid were required to increase mitochondrial energy production and ATP formation. These findings are animal data and cannot be directly extrapolated to humans.
A small human study on endurance athletes using a malate-oligosaccharide solution found that cyclists supplied with malate plus oligosaccharide solution performed the cycling to exhaustion for a longer time; the malate plus oligosaccharide solution had a good effect on maintaining a higher blood glucose concentration during exercise, increasing blood lactate removal rate, and decreasing the level of serum GOT and GPT after exercise, postponing the occurrence of fatigue. This study involved a combination product, not malate alone, and is therefore limited in its applicability.
Evidence strength: Moderate, based on multi-trial meta-analyses; specific to BCAA mixtures rather than valine-L-malate specifically.
Patients with liver cirrhosis have decreased serum concentrations of BCAAs — a group of three essential amino acids comprising valine, leucine, and isoleucine — and a reduced Fischer ratio (serum BCAA/aromatic amino acids), which are associated with poor clinical outcomes. BCAAs constituting valine, leucine, and isoleucine act as both substrates of proteins and as key regulators for various nutrient metabolisms; patients with liver cirrhosis frequently lack sufficient BCAAs and therefore suffer from various metabolic disorders.
A Cochrane systematic review including 16 randomized clinical trials compared BCAAs to placebo, diet, lactulose, or neomycin in people with cirrhosis; the results showed that BCAAs had a beneficial effect on manifestations of hepatic encephalopathy, including overt hepatic encephalopathy (RR = 0.73, 95% CI 0.61–0.88), but not minimal hepatic encephalopathy. The evidence suggests BCAAs reduce hepatic encephalopathy, but the certainty of evidence is low; the effects on all-cause mortality, nausea and diarrhoea, albumin, and nitrogen balance are uncertain because of very low-certainty evidence.
A subsequent meta-analysis of 28 studies (1,578 oral BCAA and 1,727 control group patients) found that oral BCAAs were better in preventing hepatic encephalopathy and liver-related events than controls, with risk ratios of 0.684 (95% CI 0.497–0.941; P = 0.019) and 0.788 respectively. The use of BCAA supplementation in clinical practice remains controversial, in particular with regard to the optimal dose, duration, and relative concentration of amino acids, as there was significant variability across the studies.
The administration of BCAAs can increase muscle ammonia uptake from blood and can interfere with amino acid passage throughout the blood-brain barrier with beneficial effects on both hepatic encephalopathy and sarcopenia. All evidence in this domain refers to BCAA mixtures (valine + leucine + isoleucine), not to valine alone or to valine-L-malate as a specific compound.
Evidence strength: Preliminary to weak; largely based on BCAA mixture data.
Evidence shows that BCAA supplementation slightly increases muscle mass and body mass index, with an upward trend in muscular strength and no change in fat mass; moreover, BCAA supplementation improves symptoms of hepatic encephalopathy, and is indicated as second-line therapy. Beyond their well-established role in sports nutrition, BCAAs have been widely studied in clinical contexts such as cancer, liver cirrhosis, and cachexia due to their ability to preserve muscle mass and modulate metabolism.
Evidence strength: Very weak; limited human data.
Malic acid is an intermediate compound of the TCA cycle, and its addition could increase energy production; however, there are few articles demonstrating efficacy with low toxicity of malic acid supplementation in fibromyalgia. A systematic review following PRISMA guidelines covering the period 1965 to March 2023 selected only three articles meeting inclusion criteria. Since malic acid plays an integral part in the energy-generating Krebs cycle that takes place in the human body, it makes some sense why some people choose to supplement with it for these conditions; however, there has not been a great deal of research to date to support the use of malic acid supplements for these conditions.
Evidence strength: Strong for the specific clinical indication; not applicable to general supplementation.
One well-documented clinical context in which valine (as L-valine) is supplemented in isolation or with isoleucine is in the management of maple syrup urine disease (MSUD). MSUD is a rare, inherited metabolic disorder that affects the body's ability to metabolize amino acids due to a deficiency in the activity of the branched-chain alpha-ketoacid dehydrogenase (BCKAD) complex; it particularly affects the metabolism of leucine, isoleucine, and valine; the body is not able to properly break down these amino acids, leading them to build up in urine and become toxic.
In MSUD, leucine accumulation and its metabolites cause brain toxicity, and at diagnosis rapid plasma leucine reduction is essential; valine and isoleucine supplements are necessary to promote anabolism and enable prompt reduction of plasma leucine. The toxicity of these amino acids is restricted to leucine; indeed, extra valine and isoleucine are often given during treatment. This clinical use illustrates that valine supplementation, in specific therapeutic contexts, is well-characterized and medically supervised.
No published clinical trials have reported a specific dosage for valine-L-malate as a combined compound. The following dosages are drawn from studies and clinical guidance on the individual components.
Both L-valine and L-malate are available commercially in powder and capsule forms. The powder of L-valine is not water soluble, has a bitter-sweet taste, and weighs about 3.8 grams per level measuring teaspoon. When combined in salt form as valine-L-malate, the resulting compound is typically described by manufacturers as having improved water solubility relative to free-form valine, though peer-reviewed data specifically confirming this for valine-L-malate are not currently available.
Valine is an essential amino acid for life and occurs naturally in many foods; as such, most individuals tolerate valine supplements without issue. The U.S. National Institutes of Health Dietary Supplement Label Database (DSLD) lists L-valine as an ingredient in numerous regulated dietary supplement products marketed in the United States.
High-dose valine supplementation carries documented safety signals. An animal study in mice found that L-valine supplementation at 0.30% or 0.45% in drinking water for three weeks significantly altered the morphology of Sertoli cells and germ cells within the seminiferous tubule. L-valine treatment at these doses disturbed multiple signaling pathways (including autophagy and RNA methylation) and induced apoptosis to destroy the tissue structure of mouse testis. These are animal data and their relevance to human supplementation at typical doses is unknown, but they suggest that very high doses warrant caution.
The use of BCAAs is not exempt from mild adverse events; potential adverse effects encompass esophageal reflux, enhanced insulin resistance, and disruptions in the sleep cycle.
MSUD is a rare inherited metabolic disorder affecting the metabolism of leucine, isoleucine, and valine; with MSUD, the body is not able to properly break down these amino acids, therefore leading to their accumulation in urine and toxicity. Biallelic pathogenic variants in the catalytic components of the BCKAD enzyme complex decrease its activity thereby increasing BCAA levels and causing toxicity within skeletal muscle and brain tissue. Individuals with MSUD are managed with a BCAA-restricted diet under close medical supervision; unsupervised valine supplementation would be medically contraindicated in this population.
Under normal physiological conditions, the isoleucine:leucine and leucine:valine ratios are approximately 0.5 µM and 2 µM, respectively; a disturbance in this ratio can adversely affect the uptake of these essential amino acids by both the brain and muscle tissue. Taking valine in isolation without balancing leucine and isoleucine may theoretically alter competitive transport at the LAT1 system and produce imbalances. The scientific literature on BCAA supplementation consistently emphasizes the importance of the triad together.
Epidemiological and mechanistic research has raised questions about elevated circulating BCAA levels and insulin resistance. mTOR activity regulates cellular protein turnover (autophagy) and integrates insulin-like growth signals to protein synthesis initiation across tissues; this biology has been directly linked to biogenesis of lean tissue mass in skeletal muscle, metabolic shifts in disease states of obesity and insulin resistance, and aging. The clinical significance of this concern for moderate dietary valine supplementation in otherwise healthy individuals has not been clearly established in controlled human trials.
Because valine undergoes catabolism that is disrupted in branched-chain organic acidurias and in advanced renal or hepatic disease, use in individuals with impaired nitrogen metabolism or kidney disease warrants attention. Several studies have investigated the efficacy of BCAA supplementation as a therapeutic option in liver cirrhosis, but uncertainties remain about the real efficacy, the best route of administration, and dosage. Clinical use in liver disease is medically supervised and dose-specific.
Most individuals tolerate malic acid well, given that it is a common compound in many fruits and vegetables. Accumulating evidence demonstrates that dysregulation in the physiological concentration of L-malic acid within the host is closely associated with various diseases; consequently, supplementation of L-malic acid within an appropriate range holds significant potential. The qualifier "within an appropriate range" underscores that, as with all bioactive compounds, dose-dependency governs both efficacy and safety; however, specific human safety data on high-dose malic acid supplementation are limited in the peer-reviewed literature.
The most significant limitation of the current literature is the complete absence of published human clinical trials specifically testing valine-L-malate as a combined compound. The ingredient's theoretical benefits are extrapolated from two separate bodies of evidence — one for L-valine as a BCAA component and one for L-malate as a TCA cycle intermediate — neither of which individually establishes that the combination form delivers superior or distinct outcomes compared with its individual components taken separately.
For L-valine itself, evidence in humans is almost entirely derived from BCAA mixture studies. The specific and independent contribution of valine — as opposed to leucine, which is the dominant mTOR activator within the BCAA triad — to exercise performance, protein synthesis, or clinical outcomes has not been adequately characterized in isolated human studies. Overall experimental support for the individual potency of isoleucine and valine in this context is limited.
For L-malate, while its biochemical role in the TCA cycle is well established, the science is nuanced: malate clearly matters for cellular bioenergetics, but clinical benefits depend on context, dose, and the company it keeps.
Researchers studying citrulline malate — the best-characterized analog of this class of compound — have noted that the mechanism of action of citrulline malate remains to be fully elucidated due to the synergistic impact of both components, and the limited evidence for the standard level of supplement use results in athletes' self-prescribing; further studies should continue to investigate the optimal dose, timing, mechanism of action, and reliable sources for amino acid malate supplementation. These conclusions apply equally, and arguably more so, to valine-L-malate, for which the research base is less developed.
Health conditions that Valine-l-malate may help support.
Body systems that Valine-l-malate may help support.
Go back